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ABSTRACT
Introduction: The purpose of the present study
was to determine whether the abatacept
autoinjector can be used by the intended
population without patterns of
preventable use errors, and is acceptable when
assessed against key user needs.
Methods: Two independently conducted
simulated-use studies, with no active drug
administered, quantified use errors and
evaluated the abatacept autoinjector and
competitor devices on key attributes (comfort,
control, ease of use, confidence of dose) and
overall acceptability. Autoinjector preference
was also assessed. Participants were patients
with rheumatoid arthritis, caregivers, and
healthcare professionals (HCPs). Participants
were informed that a new rheumatoid arthritis
autoinjector was being tested but were blinded
to the intended drug and sponsor identity.
Results: In the formative (pre-validation) study
(n = 54), two high-priority use errors occurred,
both of which resulted from protocol
non-compliance rather than mental confusion
or physical limitations. In the summative
(validation) study (n = 99), one high-priority
use error occurred; this was deemed a
simulated-use study artifact as participant
behavior was guided by actual experience
associated with the feel of drug delivery into
the skin rather than by protocol, so no
mitigation steps were considered necessary.
Across user groups, average scores were
consistently high for the pre-defined key
attributes. Overall acceptability scores (7-point
scale) were significantly higher for the abatacept
versus competitor autoinjectors—formative
study: patients 6.7 vs 5.2 (P = 0.0001),
caregivers 7.0 vs 4.6 (P = 0.0093), HCPs 6.8 vs
5.1 (P = 0.0020); summative study: patients 6.5
vs 5.9 (P = 0.0404), caregivers 6.8 vs 5.8
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(P = 0.0047), HCPs 6.8 vs 5.1 (P = 0.0002). The
abatacept autoinjector was preferred to
competitor devices: patients 85.7% vs 14.3%
(P = 0.00002), caregivers 84.2% vs 15.8%
(P = 0.00443), HCPs 95.0% vs 5.0%
(P = 0.00004). Positive experiences with the
abatacept autoinjector were attributed to the
rubberized grip, device size, visualization of
dose progression, button ergonomics, and ease
of use.
Conclusion: The abatacept autoinjector
demonstrated usability without patterns of
preventable use errors, and with high
acceptability ratings across all key attributes
assessed. Preference over competitor
autoinjectors was due to device ergonomics,
visualization of dose progression, confidence of
dose delivery, and overall ease of use.
Funding: Bristol-Myers Squibb.
Keywords: Abatacept autoinjector; Failure
modes and effects analysis; Human factors
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INTRODUCTION
Abatacept, a fully human fusion protein, is the
only biologic for the treatment of rheumatoid
arthritis (RA) that selectively modulates the
CD80/CD86:CD28 co-stimulatory signal
required for full T cell activation and is
available in both intravenous and
subcutaneous (SC) formulations. The
intravenous formulation of abatacept has
demonstrated efficacy in several patient
populations, including methotrexate-naive
patients with early RA [1] and patients with an
inadequate response to methotrexate [2–5] or to
anti-tumor necrosis factor therapy [6, 7]. SC
abatacept has been shown to be non-inferior to
intravenous abatacept [8, 9]. The SC
formulation, available as a pre-filled syringe,
was first approved in the US in July 2011 for the
treatment of moderate-to-severe RA in adults.
Since then, SC abatacept has received marketing
approval for the treatment of adult RA in
numerous regions, including the EU, Japan,
Canada, and Australia.
Although the SC delivery method affords
users the benefit of self-injection at home, the
pre-filled syringe requires several hand
manipulations. This can be difficult for
individuals with RA, as the disease often
affects the small joints of the hand and
impairs dexterity. To address this limitation
and increase options for patients, a pre-filled,
single-use autoinjector for abatacept
(ClickJect; Bristol-Myers Squibb, Princeton,
NJ, USA) has been developed, with the aims of
increasing the ease of the injection process and
minimizing use error risk.
The abatacept autoinjector was designed and
developed using human factors engineering
(HFE). The autoinjector has a large rubberized
grip and a hidden needle, and uses an
automated injection process including
automated delivery of the entire syringe
contents. It also incorporates visual feedback
to indicate the end of the injection, and shields
the needle after injection. These features were
designed to facilitate the injection process by
improving handling ergonomics and reducing
the number of hand manipulations, as well as to
help patients who are new to self-injection and
to overcome barriers to self-injection such as
needle phobia.
This report describes the results of two
studies that were conducted to assess the
usability and acceptability of the abatacept
autoinjector. A formative (pre-validation)
study was performed to identify aspects of the
product design and instructions for use (IFU)
that could be further optimized to reduce the
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risk of user errors, while a summative study was
performed as a final validation of the usability
of the product and its labeling.
METHODS
Two usability studies—formative and
summative—were performed to measure the
success of the HFE approach for device
development (for details of the HFE, see
Supplementary File 1). The goals of these
studies were to determine: (1) whether the
abatacept autoinjector, when provided with
IFU, can be used without patterns of
preventable use errors that would cause user or
patient harm; and (2) if the autoinjector is
acceptable for real-world use based on an
assessment of key user needs (i.e., comfort,
control, ease of use, confidence of dose) and
overall acceptability.
The summative and formative studies were
conducted by an independent company,
Ipsos-Insight, LLC, separate from the study
sponsor (Bristol-Myers Squibb). Participants
were informed that the studies were testing a
new autoinjector for an RA therapy, but no
other specifics were shared. Throughout the
studies, participants were blinded to the drug
for which the autoinjector was intended, as well
as to any sponsor involvement. Informed
consent was obtained from all patients for
being included in the study; study risks were
included in the informed consent.
Study Population
To replicate actual use, the study population
included individuals from three defined user
groups who met the following criteria: (1)
patients with RA: both injection naive and
experienced, with a minimum disease duration
of 6 months and a diagnosis of
moderate-to-severe RA (as evidenced by
current treatment with a biologic or
non-biologic disease-modifying anti-rheumatic
drug); (2) caregivers: both injection naive and
experienced, with a family member who has
been diagnosed with RA; and (3) healthcare
professionals (HCPs): injection experienced,
who routinely work with and train patients
with RA, and with a minimum of 2 years of
experience. For the summative study, a
minimum of 15 respondents per user group
were recruited in accordance with the US Food
and Drug Administration human factors
guidance [10].
In each study, users were divided into two
groups: trained and untrained (Fig. 1). To
reduce the potential for use error, users should
be trained, by an HCP, on the correct technique
for preparing and performing injections when a
therapy is prescribed, prior to the first injection.
However, because there is no guarantee that all
users will be adequately trained before their first
use, the device was also validated with
untrained participants. For the formative study
(Fig. 1a), the trained arm comprised only
patients; for the summative study (Fig. 1b), the
trained arm included both patients and
caregivers. Because most HCPs are not
expected to receive any training on how to use
the autoinjector, this group was not represented
in the trained arm of either study. Prior to the
studies, representatives from Bristol-Myers
Squibb trained a nurse educator on the correct
use of the autoinjector. The nurse educator in
turn trained patients and caregivers using only
the IFU and a device, to ensure the training was
representative of that available in a routine
clinical setting.
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Use Environment
As these were simulated-use studies, efforts were
made to simulate an end user’s actual use
environment, and the study materials were
designed to replicate the ergonomics and steps
of actual administration. Injections are typically
performed in low-traffic, low-distraction,
low-noise settings, with normal office
environment lighting conditions, and this
environment was therefore replicated at the
market research facilities where the studies were
conducted. Study materials included an
injection pad, which was strapped to the
desired injection location (abdomen or thigh)
in place of the injection site, a refrigerator
(unplugged) for device storage, a hand sanitizer
to mimic hand washing, and production-grade
devices filled with medical-grade silicone oil to
simulate the viscosity of abatacept and, hence,
the injection time. The devices did not contain
active therapy.
Study Procedures and Assessments
During the formative and summative studies,
each participant was provided with the IFU and
a device, and was asked to perform the
necessary steps per the IFU to simulate an
injection. The investigators evaluated each
step (based on a risk analysis conducted prior
to the study; see Supplementary File 1) using an
assessment checklist, based on the perceptual,
cognitive, and physical requirements of each
step. High-priority tasks were defined as those
that required correct completion for successful
dose delivery.
The investigators then rated the observed
performance as ‘correct performance’ (A),
‘performed with difficulty’ (D), or ‘use error’
(UE). A ‘performed with difficulty’
(D) classification included all close calls and
near misses in which the user experienced
confusion or difficulty, misinterpreted the IFU,
or made an error that would result in
Fig. 1 Trained and untrained user groups by study type. HCPs healthcare professionals
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mistreatment or harm, but then recovered and
was able to continue so that no actual
performance failure occurred. If a performance
error occurred, but the user self-identified that
the error had been made without prompting, it
was also considered a ‘performed with difficulty’
(D) error, since the individual acknowledged
the incorrect step and would self-correct with
subsequent usage. A ‘use error’ (UE)
classification included instances where the
participant did not complete the step as
appropriate. Following the usability
assessment, the investigator and participant
discussed the underlying causes of any
difficulties (D) or use errors (UE) encountered
during the simulated-use assessments, to
ascertain if modifications could be
incorporated into the product design or IFU to
further optimize ease of use.
Participants were also asked to rate the
acceptability of the autoinjector against a
series of key attributes (i.e., comfort, control,
ease of use, confidence of dose) and overall
acceptability using a 7-point scale (1 = very
unacceptable, 4 = neutral, and 7 = very
acceptable). If time allowed, those participants
who were experienced with an RA autoinjector
were provided with their current or most recent
autoinjector, allowed to re-familiarize
themselves with it, and asked to provide
competitive ratings. The participants did not
perform a simulated injection with the
competitor autoinjector. Participants
experienced with an RA autoinjector were also
asked for their preference of autoinjector based
on their experiences during the simulated-use
assessment.
A paired t test was used to identify statistical
significance (P\0.05) for the competitive
rating analysis, while an exact binomial test
was used for the user preference analysis.
Finally, respondents were asked to name key
positive features of the abatacept autoinjector,
based on their simulated-use experience.
RESULTS
The formative (pre-validation) study was
conducted from February to March 2014 at
market research centers in Fort Lee, NJ, USA;
Fort Lauderdale, FL, USA; and San Francisco,
CA, USA. A total of 34 patients with RA, 10
caregivers, and 10 HCPs were recruited (Fig. 1a).
The summative (validation) study was
conducted from August to September 2014 at
market research centers in Fort Lee, NJ, USA;
Baltimore, MD, USA; Stamford, CT, USA; and
Dallas, TX, USA. A total of 51 patients with RA,
33 caregivers, and 15 HCPs were recruited
(Fig. 1b). Respondents from Fort Lee, NJ, USA
who had participated in the formative study
were not eligible to participate in the
summative study. The participant
demographics are shown in Table 1.
Simulated-Use Usability Assessment
Most participants completed each individual
step of the simulation task without use errors
(Table 2). In the formative study, two use errors
were observed with the high-priority injection
steps, both related to the respondent [one
untrained patient and one HCP (i.e.,
untrained)] not holding the device in place
long enough to complete the injection.
Although these errors were observed,
post-study actions were not taken to modify
the device design or labeling, since the
root-cause analysis identified the outcome to
be a result of the respondents’ non-compliance
to the protocol and study methodology, rather
than a result of mental confusion or physical
limitations. However, minor layout changes
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were made to the IFU to improve compliance
with two (low-priority risk) use steps: ‘pinch
skin’ and ‘check the autoinjector for damage’.
In the summative study, all participants
except one (an untrained patient) completed
all of the high-priority injection steps (Table 2).
The exception related to the ‘hold for count
and/or wait until blue indicator stops moving’
step. The use error was deemed an artifact of the
study, as the patient was currently using a
competitor autoinjector and was applying their
expectations of the ‘feel’ in the skin of an
injection to indicate the appropriate hold time.
Since this tactile end-of-dose indication does
not apply to a simulated-use setting, no
mitigation steps were deemed necessary.
Simulated-Use Acceptability Assessment
Average acceptability scores for the device were
consistently high for each user group for all
measures (comfort, control, ease of use,
confidence of dose, overall acceptability)
(Table 3). In the formative study, all 54
participants responded (34 patients, 10
caregivers, and 10 HCPs); mean overall
acceptability scores (out of 7) for patients,
caregivers, and HCPs were 6.6, 7.0, and 6.8,
respectively. In the summative study, 94 out of
99 participants responded (48 patients, 31
caregivers, and 15 HCPs); mean overall
acceptability scores for patients, caregivers,
and HCPs were 6.6, 6.8, and 6.8, respectively.
Current Autoinjector User Subgroup
Analysis
Among patients who had previously
administered injections with a competitor
autoinjector, overall mean acceptability ratings
were significantly greater for the abatacept
autoinjector versus competitor autoinjectors
across all user groups in both studies
[formative study: patients 6.7 vs 5.2
(P = 0.0001), caregivers 7.0 vs 4.6 (P = 0.0093),
HCPs 6.8 vs 5.1 (P = 0.0020); summative study:
patients 6.5 vs 5.9 (P = 0.0404), caregivers 6.8 vs
5.8 (P = 0.0047), HCPs 6.8 vs 5.1 (P = 0.0002);
Table 4]. In the individual categories of comfort,
control, ease of use, and confidence of dose, all
Table 3 Participant user experience data















Comfort 6.5 (0.8) 6.6 (1.0) 6.8 (0.6) 6.4 (1.0) 6.3 (1.0) 6.9 (0.4)
Control 6.6 (0.9) 6.8 (0.4) 6.7 (1.0) 6.9 (0.4) 6.8 (0.5) 6.8 (0.4)
Ease of use 6.7 (0.8) 6.9 (0.3) 6.8 (0.4) 6.6 (0.8) 6.9 (0.3) 6.7 (0.6)
Conﬁdence of dose 6.8 (0.5) 7.0 (0.0) 6.4 (1.6) 6.6 (0.7) 6.9 (0.4) 6.7 (0.6)
Overall acceptability 6.6 (0.8) 7.0 (0.0) 6.8 (0.4) 6.6 (0.6) 6.8 (0.5) 6.8 (0.4)
All values are expressed as mean (standard deviation)
Each score was quantiﬁed using a 7-point scale, where 1 = very unacceptable, 4 = neutral, and 7 = very acceptable
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groups rated the abatacept autoinjector at least
the same or superior to competitor
autoinjectors; this difference was significant
for almost all parameters, across all user
groups, and in both studies (Table 4).
Participants demonstrated a strong
preference for the abatacept autoinjector over
competitor autoinjectors (Table 5). When
preference data from the two studies were
combined, a significantly greater number of
participants in each user group preferred the
abatacept autoinjector over their current or
most recent autoinjector [patients 85.7% vs
14.3% (P = 0.00002), caregivers 84.2% vs
15.8% (P = 0.00443), HCPs 95.0% vs 5.0%
(P = 0.00004)]. For the individual studies, this
preference remained significant for patients in
the formative (P = 0.00049) and summative
(P = 0.01062) studies, and for HCPs in the
summative study (P = 0.00049). Although the
other comparisons were not significant, all
preference data showed at least a trend in
favor of the abatacept autoinjector in both
studies.
Key Positive Features
In total, 31 formative study participants and 87
summative study participants reported on the
positive features of the abatacept autoinjector.
The most frequently noted positive features
were: rubberized grip (formative study, noted
by 58% of respondents; summative study, 56%),
device size (formative, 55%; summative, 52%),
visualization of dose progression (window size
and location, colored plunger rod; formative,
45%; summative, 57%), button ergonomics
(shape, reach, activation force; formative, 19%;
summative, 37%), and ease of use (number of
steps, simplicity; formative, 29%; summative,
30%) (Fig. 2).
DISCUSSION
The independently conducted studies reported
here found that the newly designed autoinjector
for the SC delivery of abatacept in patients with
RA was easy to use, with low residual risk to users
ina real-world setting.Most participants,whether
patients, caregivers, or HCPs, trained or
untrained, performed all high-priority use steps
correctly. Participants rated the abatacept
autoinjector highly for user experience in terms
of comfort, control, ease of use, confidence of
dose, and overall acceptability, with scores
nearing the maximum of the 7-point scale used.
All user groups across both studies rated the
abatacept autoinjector significantly higher than
competitor devices for overall acceptability, and
when preference data from both studies were
combined, significantlymoreparticipants in each
user group preferred the abatacept autoinjector
over their current or most recent device. The
drivers for the positive ratings and preference
could be grouped into three main categories:
device ergonomics (size, rubberized grip, button
reach, force to activate), which provides comfort
and security during injection; visualization of
dose progression (size and location of window,
colored plunger rod), which provides confidence
of dose delivery; and simplicity of the process,
which contributes to the overall ease of use of the
device.
Because RA can affect the small joints of the
hands, many patients with RA suffer from
compromised dexterity. In addition to
interfering with activities of daily living, poor
dexterity can affect the ability to perform the
steps required for self-injection in patients who
would otherwise be eligible for an SC therapy.
Autoinjectors are available for the
administration of many SC therapies for
chronic conditions, including those in which





















































































































































































































































































































































































































































































































210 Adv Ther (2016) 33:199–213
patients have impaired dexterity [11, 12]. The
single-use, pre-filled autoinjector described here
was developed following the principles ofHFE, to
help users to inject one dose of SC abatacept in a
home environment. As evidenced by the results
of the current studies, the new autoinjector is an
important advance for patients receiving, or
eligible to receive, SC abatacept, as it increases
the ease of the injection process without
introducing usability challenges.
In both the formative and summative
studies, the vast majority of respondents
completed each individual step of the
simulated injection without use errors. These
results demonstrate that, overall, both trained
and untrained users were able to operate the
autoinjector safely and effectively to deliver the
SC injection by following the IFU.
Furthermore, the overall preference in favor
of the abatacept autoinjector over other
available injection devices across a range of
attributes indicates that the device’s features
were favored by users with experience of such
devices. The fact that similar results were
obtained across the two studies provides
further credence to these findings. These data
also indicate that the device features designed
in early development (i.e., shape, rubberized
Fig. 2 Key positive factors of the abatacept autoinjector reported by respondents
Adv Ther (2016) 33:199–213 211
grip, placement/size of window, colored
plunger rod, button ergonomics) contributed
to the favorable comfort, control, confidence of
dose, ease of use, and acceptability ratings for
the device, indicating value by the end users.
Furthermore, as no patterns of error were
observed in the studies, use risk was mitigated.
A limitation of these evaluations is the
simulated-use design of the studies, rather than
autoinjector use in a clinical setting. However,
according to US Food and Drug Administration
guidance, simulation testing, as conductedhere, is
an acceptable method for assessing the safe and
effective use of an autoinjector device. Greater
support for the ease of use of the autoinjectormay
have been obtained by restricting the study
population to patients with more severe hand
deformity, for whom any improvement would be
most beneficial. In addition, respondent numbers
were low in the subgroup analyses. A further
limitation is the lackof a simulated injectionusing
the competitor autoinjector device; permitting a
simulated injection with a competitor device may
have allowed for amore accurate comparisonwith
the abatacept autoinjector versus relying on
participant memory. The time span between
using and rating the competitor device may have
influenced the comparative data; therefore, not
capturing and adjusting for this time difference
may affect the interpretation of these results.
Lastly, the autoinjector was branded in order for
participants to evaluate its coloreddesign features.
As such, HCPs may have ascertained which
product the autoinjector was designed to deliver.
CONCLUSIONS
Theabatacept autoinjectorwas found tobehighly
acceptable against key measures of comfort,
control, ease of use, confidence of dose, and
overall acceptability in two independently
conducted simulated-use studies. High overall
acceptability ratings were achieved, and these
ratings were significantly greater than those for
competitor devices. In addition, a significantly
greater number of participants in each user group
preferred the abatacept autoinjector over their
current or most recent autoinjector.
Participants’ positive experiences with the
abatacept autoinjector can be attributed to the
following key features: device ergonomics (size,
shape, rubberized grip, button reach, and
activation force), which provides comfort and
security during injection; visualization of dose
progression (size and location of window,
colored plunger rod), which provides
confidence of dose delivery; and simplicity of
the process, which contributes to the overall
ease of use of the device. These results show that
HFE optimized the device design and IFU of the
abatacept autoinjector to ensure its effective use
by patients, caregivers, and HCPs without
patterns of preventable use errors.
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